NIH
-
Improving vaccine formulations
The compound MPLA is an attractive vaccine component, designed to elicit a robust immune response. Read MoreJanuary 20, 2017
-
Colorectal cancer clues
Although cancers arising from different areas of the large intestine are heterogeneous, they appear to use similar important tumorigenic pathways. Read MoreJanuary 19, 2017
-
Surprising finding by VU team sheds light on fibrotic disease
Integrins are membrane proteins made up of combinations of different “alpha” and “beta” subunits that enable cells throughout the body to interact with their surroundings. Read MoreJanuary 19, 2017
-
Metastatic pancreatic cancer ‘reprograms’ for malignancy
Metastatic pancreatic cancer — cancer that has spread from the pancreas to other tissues and is responsible for most patient deaths — changes its metabolism and is “reprogrammed” for optimal malignancy, according to new findings reported Jan. 16 in Nature Genetics. Read MoreJanuary 19, 2017
-
Softening tumor tissue could aid cancer treatments
Tumors cause the intracellular material surrounding them to stiffen. Softening this protective layer could make existing cancer treatments more effective, according to new research. Read MoreJanuary 16, 2017
-
DNA duplicator small enough to hold in your hand
Vanderbilt engineers have developed a new method for duplicating DNA that makes devices small enough to hold in your hand that are capable of identifying infectious agents before symptoms appear. Read MoreJanuary 11, 2017
-
Midgut neuroendocrine tumor prognosis
Vanderbilt investigators recommend that the presence of tumor deposits in the abdomen be included when staging midgut neuroendocrine tumors. Read MoreJanuary 6, 2017
-
Department of Medicine’s NIH funding swells
Vanderbilt University School of Medicine has long been recognized as a national leader in biomedical research. Nowhere is this more evident than in the school’s Department of Medicine, which, during the 2016 federal fiscal year that ended Sept. 30, broke another record. Read MoreJanuary 5, 2017
-
Investigational new drug for Alzheimer’s scheduled for first study in humans
Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center. Read MoreDecember 27, 2016
-
Discovery sheds new light on Angelman, Prader-Willi syndromes
A mutation associated with epilepsy and autism also is responsible for a “pale eye” trait in two rare genetic disorders, Angelman syndrome and Prader-Willi syndrome, neuroscientists at Vanderbilt University Medical Center reported this week. Read MoreDecember 22, 2016